Voxilaprevir
 | |
| Clinical data | |
|---|---|
| Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
| Identifiers | |
| |
JSmol) | |
| Density | 1.4±0.1[1] g/cm3 |
| |
| |
Voxilaprevir is a
Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4]
References
- ^ "voxilaprevir_msds".
- S2CID 4395880.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C
